133 related articles for article (PubMed ID: 29787374)
1. Evaluating the impact of the genitourinary multidisciplinary tumour board: Should every cancer patient be discussed as standard of care?
Scarberry K; Ponsky L; Cherullo E; Larchian W; Bodner D; Cooney M; Ellis R; Maclennan G; Johnson B; Tabayoyong W; Abouassaly R
Can Urol Assoc J; 2018 Sep; 12(9):E403-E408. PubMed ID: 29787374
[TBL] [Abstract][Full Text] [Related]
2. Thoracic multidisciplinary tumor board routinely impacts therapeutic plans in patients with lung and esophageal cancer: a prospective cohort study.
Schmidt HM; Roberts JM; Bodnar AM; Kunz S; Kirtland SH; Koehler RP; Hubka M; Low DE
Ann Thorac Surg; 2015 May; 99(5):1719-24. PubMed ID: 25678503
[TBL] [Abstract][Full Text] [Related]
3. Multidisciplinary Cancer Management of Colorectal Cancer in Tikur Anbessa Specialized Hospital, Ethiopia.
Deressa BT; Cihoric N; Tefesse E; Assefa M; Zemenfes D
J Glob Oncol; 2019 Oct; 5():1-7. PubMed ID: 31589543
[TBL] [Abstract][Full Text] [Related]
4. Primary Results of Patients with Genitourinary Malignancies Presented at a Molecular Tumor Board.
Michaelis J; Himmelsbach R; Metzger P; Lassmann S; Börries M; Werner M; Miething C; Höfflin R; Illert AL; Duyster J; Becker H; Sigle A; Gratzke C; Grabbert M
Urol Int; 2024 Apr; ():1-9. PubMed ID: 38626735
[TBL] [Abstract][Full Text] [Related]
5. Pre-diagnosis Multidisciplinary Tumor Board and Time to Staging in Lung Cancer: The Case Western MetroHealth Experience.
Thalanayar Muthukrishnan P; Ratnam M; Nguyen MT; Le M; Gunzler D; Bruno D; Infeld M
Cureus; 2020 Jan; 12(1):e6595. PubMed ID: 32064177
[TBL] [Abstract][Full Text] [Related]
6. Contribution of FDG-PET/CT to the management of esophageal cancer patients at multidisciplinary tumor board conferences.
Shashi KK; Madan R; Hammer MM; van Hedent S; Byrne SC; Schmidlin EJ; Mamon H; Hatabu H; Enzinger PC; Gerbaudo VH
Eur J Radiol Open; 2020; 7():100291. PubMed ID: 33304940
[TBL] [Abstract][Full Text] [Related]
7. Genitourinary non-tuberculous mycobacterial (GU-NTM) infections: A single institution experience in South India.
Sali G; Kalavampara SV; Kandasamy SG; Kumar A; Mathew G; Thomas A
Indian J Tuberc; 2021 Jan; 68(1):65-72. PubMed ID: 33641853
[TBL] [Abstract][Full Text] [Related]
8. Physician compliance with multidisciplinary tumor board recommendations for managing gynecological cancers.
Naessens C; Laloze J; Leobon S; Gauthier T; Lacorre A; Monteil J; Venat L; Deluche E
Future Oncol; 2023 Apr; 19(13):897-908. PubMed ID: 37232140
[TBL] [Abstract][Full Text] [Related]
9. Artificial intelligence in urologic oncology: the actual clinical practice results of IBM Watson for Oncology in South Korea.
Park T; Gu P; Kim CH; Kim KT; Chung KJ; Kim TB; Jung H; Yoon SJ; Oh JK
Prostate Int; 2023 Dec; 11(4):218-221. PubMed ID: 38196551
[TBL] [Abstract][Full Text] [Related]
10. A multidisciplinary approach to the management of urologic malignancies: does it influence diagnostic and treatment decisions?
Kurpad R; Kim W; Rathmell WK; Godley P; Whang Y; Fielding J; Smith L; Pettiford A; Schultz H; Nielsen M; Wallen EM; Pruthi RS
Urol Oncol; 2011; 29(4):378-82. PubMed ID: 19576797
[TBL] [Abstract][Full Text] [Related]
11. The impact of multidisciplinary team conferences in urologic cancer in a tertiary hospital.
Gil M; Guerra J; Andrade V; Medeiros M; Guimarães T; Bernardino R; Falcão G; Calais da Silva F; Campos Pinheiro L
Int Urol Nephrol; 2021 Jan; 53(1):41-47. PubMed ID: 32816157
[TBL] [Abstract][Full Text] [Related]
12. A prospective study of the clinical impact of a multidisciplinary head and neck tumor board.
Wheless SA; McKinney KA; Zanation AM
Otolaryngol Head Neck Surg; 2010 Nov; 143(5):650-4. PubMed ID: 20974334
[TBL] [Abstract][Full Text] [Related]
13. Do Multidisciplinary Tumor Board Discussions Correlate With Increase in 5-Year Survival? A Meta-Analysis Study.
Algwaiz G; Salam Y; Bustami R; Ferwana M; Jazieh AR
Glob J Qual Saf Healthc; 2021 Feb; 4(1):3-10. PubMed ID: 37260532
[TBL] [Abstract][Full Text] [Related]
14. Multidisciplinary management improves survival at 1 year after surgical treatment for non-small-cell lung cancer: a propensity score-matched study.
Tamburini N; Maniscalco P; Mazzara S; Maietti E; Santini A; Calia N; Stefanelli A; Frassoldati A; Santi I; Rinaldi R; Nigim F; Righi R; Pedrazzi S; Cavallesco G
Eur J Cardiothorac Surg; 2018 Jun; 53(6):1199-1204. PubMed ID: 29293943
[TBL] [Abstract][Full Text] [Related]
15. Uro-oncology multidisciplinary meetings at an Australian tertiary referral centre--impact on clinical decision-making and implications for patient inclusion.
Rao K; Manya K; Azad A; Lawrentschuk N; Bolton D; Davis ID; Sengupta S
BJU Int; 2014 Nov; 114 Suppl 1():50-4. PubMed ID: 25070295
[TBL] [Abstract][Full Text] [Related]
16. Implementation of a molecular tumour board in LATAM: the impact on treatment decisions for patients evaluated at Instituto Alexander Fleming, Argentina.
Angel MO; Pupareli C; Soule T; Tsou F; Leiva M; Losco F; Esteso F; O Connor JM; Luca R; Petracci F; Girotti R; Mahmoud YD; Martín C; Chacón M
Ecancermedicalscience; 2021; 15():1312. PubMed ID: 35047063
[TBL] [Abstract][Full Text] [Related]
17. Effect of Multidisciplinary Case Conferences on Physician Decision Making: Breast Diagnostic Rounds.
Foster TJ; Bouchard-Fortier A; Olivotto IA; Quan ML
Cureus; 2016 Nov; 8(11):e895. PubMed ID: 28018765
[TBL] [Abstract][Full Text] [Related]
18. The impact of the multidisciplinary tumor board on head and neck cancer outcomes.
Liu JC; Kaplon A; Blackman E; Miyamoto C; Savior D; Ragin C
Laryngoscope; 2020 Apr; 130(4):946-950. PubMed ID: 31095740
[TBL] [Abstract][Full Text] [Related]
19. Receipt of Survivorship Care Plans and Self-Reported Health Status among Patients with Genitourinary Malignancy.
Linscott JA; Rutan MC; Han PKJ; Hansen MH; Hayn MH; Ryan ST; Trinh QD; Sammon JD
J Urol; 2020 Sep; 204(3):564-569. PubMed ID: 32267200
[TBL] [Abstract][Full Text] [Related]
20. Survival Impact and Cost-Effectiveness of a Multidisciplinary Tumor Board for Breast Cancer in Mozambique, Sub-Saharan Africa.
Brandão M; Guisseve A; Bata G; Firmino-Machado J; Alberto M; Ferro J; Garcia C; Zaqueu C; Jamisse A; Lorenzoni C; Piccart-Gebhart M; Leitão D; Come J; Soares O; Gudo-Morais A; Schmitt F; Tulsidás S; Carrilho C; Lunet N
Oncologist; 2021 Jun; 26(6):e996-e1008. PubMed ID: 33325595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
